Roche Heart Attack Testing Tech Gets OK From FDA
Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowIndianapolis-based Roche Diagnostics has received a key clearance from the U.S. Food and Drug Administration. Roche says it will be the first company of its kind in the U.S. to provide this type of technology for patients that may be experiencing a heart attack. The Elecsys Troponin T Gen 5 STAT test measures a specific marker in the blood stream that is released when heart cells are being damaged.
The company says 8 million emergency room visits per year are attributed to potential heart attack symptoms, but only 5-20 percent of them have actually suffered one. Roche Diagnostics says the test has been available throughout the rest of the world for the last seven years.
You can connect to more about the Troponin T Gen 5 STAT blood test approval by clicking here.